Blog
RSS FeedPosted by Michael Wonder on 05 Feb 2026
PHARMAC proposes wider access to a treatment for people with a rare blood cancer
4 February 2026 - People in New Zealand living with a rare type of blood cancer, systemic anaplastic large cell ...
Posted by Michael Wonder on 01 Feb 2026
New Zealand Pharmaceutical Schedule - 1 February 2026
1 February 2026 - The February 2026 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 22 Jan 2026
PHARMAC proposes to fund life changing treatments for people with cystic fibrosis
22 January 2026 - PHARMAC is proposing to fund new treatment options for people living with cystic fibrosis with eligible mutations, ...
Posted by Michael Wonder on 20 Jan 2026
New iron treatment proposed for people who have experienced low phosphate levels
20 January 2026 - PHARMAC is asking for feedback on a proposal to fund a new iron treatment, ferric derisomaltose (Monofer), ...
Posted by Michael Wonder on 12 Jan 2026
PHARMAC funds treatment for rare disorders
12 January 2026 - PHARMAC will fund nitisinone for people with the rare disorders tyrosinaemia type 1 and alkaptonuria from ...
Posted by Michael Wonder on 02 Jan 2026
New Zealand Pharmaceutical Schedule - 1 January 2026
1 January 2026 - The January 2026 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 16 Dec 2025
Updated information about PHARMAC’s priority lists as at 15 December 2025
15 December 2025 - PHARMAC’s Prioritisation Update provides the latest information about applications for medicines, vaccines, and related products that ...
Posted by Michael Wonder on 02 Dec 2025
New Zealand Pharmaceutical Schedule - 1 December 2025
1 December 2025 - The December 2025 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 28 Nov 2025
PHARMAC proposes funding for rare disorder treatment
26 November 2025 - PHARMAC is proposing to fund nitisinone for people with the rare disorders - tyrosinaemia type 1 ...
Posted by Michael Wonder on 22 Nov 2025
PHARMAC proposes funding another ADHD medicine to improve supply
20 November 2025 - Pharmac is asking for feedback on a proposal to fund another brand of methylphenidate to increase ...
Posted by Michael Wonder on 20 Nov 2025
Welcoming Natalie McMurtry, Chief Executive of PHARMAC
19 November 2025 - In September Natalie McMurtry joined PHARMAC as our new Chief Executive. ...
Posted by Michael Wonder on 13 Nov 2025
PHARMAC to fund alternative treatment for tooth decay
12 November 2025 - PHARMAC will fund silver diamine fluoride for the treatment and prevention of tooth decay from 1 December ...
Posted by Michael Wonder on 12 Nov 2025
PHARMAC to fund five medicines for multiple sclerosis, breast cancer, eye conditions, and lung cancer
12 November 2025 - New Zealanders living with multiple sclerosis, breast cancer, eye conditions, and lung cancer will benefit from ...
Posted by Michael Wonder on 08 Nov 2025
PHARMAC consults on changes to simplify biologic medicine funding criteria
6 November 2025 - PHARMAC is proposing changes to the Special Authority and Hospital Indication Restrictions criteria for four biologic ...
Posted by Michael Wonder on 31 Oct 2025
New Zealand Pharmaceutical Schedule - 1 November 2025
1 November 2025 - The November 2025 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...